FKGK11

FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2) . FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis[1][2].

Product Specifications

CAS Number

[1071000-98-0]

UNSPSC

12352005

Target

Phospholipase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/fkgk11.html

Concentration

17.84 mM * 200 μL in Ethanol

Purity

99.00

Solubility

10 mM in DMSO

Smiles

O=C(C(F)(C(F)(F)F)F)CCCCC1=CC=CC=C1

Molecular Formula

C13H13F5O

Molecular Weight

280.23

References & Citations

[1]Kokotos G, et al. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53 (9) :3602-10.|[2]Yan Xu, et al. Abstract 3525: Targeting Group VIA phospholipase A2 using small molecules for ovarian cancer treatment. Cancer Res (2011) 71 (8_Supplement) : 3525.|[3]López-Vales R, et al. Intracellular phospholipase A (2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury. Brain. 2008 Oct;131 (Pt 10) :2620-31.